These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30838379)

  • 21. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
    Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
    Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.
    Gouda MA; Polivka J; Huang HJ; Treskova I; Pivovarcikova K; Fikrle T; Woznica V; Dustin DJ; Call SG; Meric-Bernstam F; Pesta M; Janku F
    ESMO Open; 2022 Feb; 7(1):100357. PubMed ID: 34942440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
    Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
    J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 27. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
    Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
    Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
    Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
    Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
    Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
    Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
    Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
    Lucci A; Hall CS; Patel SP; Narendran B; Bauldry JB; Royal RE; Karhade M; Upshaw JR; Wargo JA; Glitza IC; Wong MKK; Amaria RN; Tawbi HA; Diab A; Davies MA; Gershenwald JE; Lee JE; Hwu P; Ross MI
    Clin Cancer Res; 2020 Apr; 26(8):1886-1895. PubMed ID: 32015020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
    Geoffrois L; Harlé A; Sahki N; Sikanja A; Granel-Brocard F; Hervieu A; Mortier L; Jeudy G; Michel C; Nardin C; Huin-Schohn C; Merlin JL
    BMC Cancer; 2023 Jun; 23(1):554. PubMed ID: 37328818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
    Brunsgaard EK; Bowles TL; Asare EA; Grossmann K; Boucher KM; Grossmann A; Jackson JA; Wada DA; Rathore R; Budde G; Grandemange A; Hyngstrom JR
    Melanoma Res; 2023 Jun; 33(3):184-191. PubMed ID: 37040662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.